Vision Breakthrough: Can a Vitrectomy with Dexamethasone Implant Restore Sight in Diabetic Macular Edema?
"Exploring a Minimally Invasive Surgical Approach to Treating Persistent Diabetic Macular Edema."
Diabetic macular edema (DME) stands as a leading cause of vision loss among working-age adults in industrialized nations, affecting approximately 7% of individuals with diabetes in Germany alone. When DME progresses unchecked, it can lead to blindness, highlighting the critical importance of timely and effective intervention.
The current standard of care typically involves anti-VEGF (vascular endothelial growth factor) therapy, which aims to reduce both proliferation and edema. However, a notable subset of patients experiences limited or no response to this treatment, resulting in persistent macular edema and continued vision decline. This lack of response suggests that anti-VEGF therapy may not address all the pro-inflammatory cytokines implicated in DME.
In light of these challenges, innovative strategies have emerged, including the intravitreal application of dexamethasone implants. This approach targets multiple processes within the inflammatory cascade, aiding in the restoration of the blood-retina barrier. Corticosteroids, known for their ability to counteract various inflammatory mediators, present a promising alternative to anti-VEGF therapy by reducing retinal leukostasis and vascular endothelial ICAM expression, thereby suppressing leukocyte adhesion and transmigration.
DME’s National Burden
Diabetic macular edema (DME) occurs when retinal blood vessels leak fluid into the macula and can occur alone or with any stage of diabetic retinopathy. Nationally representative data indicate that DME affects 3.8% of U.S. adults aged 40 years and older with diabetes, while vision-threatening diabetic retinopathy affects 4.4%. Diabetic maculopathy is described as the most common mechanism of visual impairment among people with diabetic retinopathy, which is a leading cause of vision loss in working-age adults. Medicare research has also examined ten-year trends in DME diagnosis and treatment among patients aged 65 years and older.
Established Treatment, Persistent Challenges
Clinical practice guidelines for diabetic macular edema are the subject of systematic review, reflecting the range and evolving nature of management recommendations. A historical management strategy review notes that studies of macular edema included multiple causes, making statistical significance difficult to establish; of 2,603 eyes reported, 870 were specifically associated with diabetes. Treatment evidence must therefore be interpreted in the context of differing DME causes and study populations. More recent reviews continue to evaluate pharmacologic options, including anti-VEGF therapies and agents such as conbercept.
From Vitreous Mechanics to Anti-VEGF
DME has been identified as the most common cause of moderate visual loss in people with diabetes. The vitreous was recognized as a contributor to both tractional and non-tractional DME, and modern pars plana vitrectomy techniques enabled removal of the vitreous and posterior hyaloid to relieve vitreomacular traction and remove inflammatory factors thought to contribute to DME. Additional surgical techniques include endolaser. After the successful use of anti-VEGF injections for neovascular age-related macular degeneration, similar injections were evaluated for DME and proliferative diabetic retinopathy.
Combining Vitrectomy and Dexamethasone: A New Hope for Refractory DME?
Another method to combat DME is vitrectomy. It has been suggested that vitrectomy enhances both retinal oxygen supply and overall anatomical and functional outcomes. Furthermore, removing the vitreous body may decrease the concentration of antigens and inflammatory mediators in the vitreous space, disrupting the chronic inflammatory environment. There is much evidence of vitrectomy's effects.
- The study included patients with DME for at least 12 months, all of whom had undergone MIV25 vitrectomy with DEX implantation.
- Researchers then evaluated best-corrected visual acuity (BCVA) and central retinal thickness post-surgery.
- The study involved 18 eyes, with initial BCVA averaging 0.90 logMAR and central retinal thickness at 594 µm.
- Post-intervention, central retinal thickness decreased until the third month, gradually increasing again by the sixth month but stabilizing by the twelfth month.
- Five eyes required additional treatments five months post-operation.
- Significantly, BCVA improved from one month post-treatment across all follow-up visits (p < 0.001).
Evidence in Refractory DME
Recent research is examining vitrectomy for refractory and cystoid forms of diabetic macular edema, including surgery performed with and without cystotomy. A 2025 multicenter study evaluated vitrectomy with and without cataract surgery, while its report notes that DRCR.net found decreased vision in 13% to 31% of patients despite reduced edema, leaving vitrectomy’s efficacy uncertain. Reviews of persistent DME emphasize that standard treatments can be effective but may have limitations in persistent and chronic persistent disease. A 2016 report specifically described vitrectomy with a dexamethasone implant for treatment-refractory DME.
Future Directions and Considerations
Despite these limitations, simultaneous vitrectomy and slow-release dexamethasone devices present a promising alternative for treating persistent DMÖ. This pilot study should be confirmed in a larger patient population.
Why Combined Treatment Matters
DME involves abnormal fluid accumulation within and eventually beneath the macula after breakdown of the blood-retinal barrier, pericyte loss, and endothelial junction disruption. Vitrectomy with an intraoperative dexamethasone implant has been studied for non-tractional, refractory DME, including a retrospective consecutive interventional study of 43 eyes. Other research has examined vitrectomy with internal limiting membrane peeling as an adjunct to a treat-and-extend anti-VEGF regimen. Together, these studies frame combined surgical and pharmacologic treatment as an approach under evaluation rather than a guaranteed restoration of sight.
A Broader Treatment Pipeline
The diabetic retinopathy and diabetic macular edema treatment pipeline continues to evolve. Recent coverage describes current treatments under study and considers what future therapies for diabetic eye disease may look like. Another overview examines the therapeutic landscape and treatment pipeline for both diabetic retinopathy and DME. These sources support continued development and evaluation of new options, but they do not establish that any particular future therapy will restore sight.
Outcomes Beyond the Operating Room
A retrospective consecutive interventional study investigated long-term outcomes after vitrectomy combined with intraoperative dexamethasone implants for non-tractional refractory DME. The study included 43 eyes and evaluated the need for additional non-surgical treatment after vitrectomy using a Kaplan-Meier curve. Related randomized research has examined recruitment and efficacy outcomes when vitrectomy with internal limiting membrane peeling is added to a treat-and-extend anti-VEGF regimen. These findings highlight that real-world impact includes durability and the possible need for further treatment, not only initial surgery.